Interview with Dr James Garner, CEO of Kazia Therapeutics
-
Regulatory May 25, 2022Report from Annual General Meeting in Vivesto AB
-
Regulatory May 25, 2022Interim report for the period January 1, 2022 – March 31, 2022
-
Non Regulatory May 18, 2022Invitation to presentation of Vivesto’s Q1 report 2022 on May 25
Vivesto published its Q1 2022 report on May 25, 2022, at 08.00 am CET.
Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program
Today we published our Q1 #Financial #Results.
In a challenging financial climate, we were pleased to successfully raise SEK 151m during the quarter and report operational progress on several fronts.
#oncology #biotech
Interim report for the period January 1, 2022 – March 31, 2022 - Vivesto
SIGNIFICANT EVENTS DURING THE FIRST QUARTER
bit.ly
Did you know that #WorldOvarianCancerDay is on May 8? We are proud to be developing new treatments that we hope may make a difference to patients. Learn more about ovarian cancer and check out its symptoms here:
#WOCD2022 #NoWomanLeftBehind
Home
The World Ovarian Cancer Coalition
worldovariancancercoalition.org
